Development of a Nanoemulsion Adjuvant with a Vaccine for Pandemic Influenza

大流行性流感疫苗纳米乳佐剂的开发

• 批准号: 8751859
• 负责人: Ali I. Fattom
• 金额: $ 551.62万
• 依托单位: BLUEWILLOW BIOLOGICS, INC.
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-30 至 2016-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8751859
• 关键词: Adjuvant; Animals; Antigens; Cyclic GMP; Development; Drug Formulations; Emerging Communicable Diseases; Engineering; Equilibrium; Ferrets; Glycoproteins; HIV; Human; Immune response; Infection; Intramuscular; Investigational Drugs; Lead; Licensing; Licensure; Molecular Conformation; Mus; National Institute of Allergy and Infectious Disease; Oils; Oryctolagus cuniculus; Plants; Program Development; Recombinants; Research; Route; Self Administration; Testing; Vaccine Adjuvant; Vaccines; Virus-like particle; Water; base; clinical toxicology; immunogenicity; influenza virus vaccine; manufacturing scale-up; nanoemulsion; novel; pandemic influenza; pathogen; pre-clinical; stability testing

The NIAID/DAIT Adjuvant Development Program supports the development of new candidate vaccine adjuvants through immunological characterization studies and lead compound optimization, up to and including IND-enabling studies, all towards licensure for human use. Adjuvants will be studied with currently licensed or new investigational vaccines to protect against infection by NIAID emerging and re-emerging infectious disease pathogens.

NIAID/DAIT佐剂开发计划支持通过免疫学表征研究和先导化合物优化开发新的候选疫苗佐剂，直至并包括IND使能研究，所有这些都是为了获得人用许可。佐剂将与目前许可的或新的研究疫苗一起研究，以防止NIAID新发和再发传染病病原体的感染。